Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer

Preclinical evaluation of avutometinib and defactinib in high‐grade endometrioid endometrial cancer

Abstract Background High‐grade endometrial cancers (EAC) are aggressive tumors with a high risk of progression after treatment. As EAC may harbor mutations in the RAS/MAPK pathways, we evaluated the preclinical in vitro and in vivo efficacy of avutometinib, a RAF/MEK clamp, in combination with the f...

Full description

Saved in:
Bibliographic Details
Main Authors: Tobias Max Philipp Hartwich, Miranda Mansolf, Cem Demirkiran, Michelle Greenman, Stefania Bellone, Blair McNamara, Shuvro P. Nandi, Ludmil B. Alexandrov, Yang Yang‐Hartwich, Silvia Coma, Jonathan Pachter, Alessandro D. Santin
Format: Article
Language:English
Published: Wiley 2024-09-01
Series:Cancer Medicine
Subjects:
avutometinib
defactinib
endometrial cancer
FAK inhibitor
MEK inhibitor
Online Access:https://doi.org/10.1002/cam4.70210
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1002/cam4.70210

Similar Items